Endometrium adenocarcinoma
MONDO:0005461An adenocarcinoma arising from the uterine body cavity. This is the most frequent malignant tumor affecting the uterine body, and is linked to estrogen therapy. Most patients present with uterine bleeding and are over age 40 at the time of diagnosis. The prognosis depends on the stage of the tumor, the depth of the uterine wall invasion, and the histologic subtype. Endometrioid adenocarcinoma is the most frequently seen morphologic variant of endometrial adenocarcinoma.
Also known as: endometrioid carcinoma of endometrium, adenocarcinoma of endometrium, adenocarcinoma of the endometrium, adenocarcinoma, endometrial, malignant, endometrial adenocarcinoma, endometrioid adenoma or carcinoma NOS (morphologic abnormality), endometrioid adenomas and carcinomas (morphologic abnormality), endometrium adenocarcinoma
2954 clinical trials for this condition and its sub-types, 30 tagged with Endometrium adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Endometrium adenocarcinoma
-
Ovarian endometrioid adenocarcinoma 77 trials
1 sub-type
-
Endometrial clear cell adenocarcinoma 21 trials
-
Endometrial mixed adenocarcinoma 10 trials
-
Endometrial mucinous adenocarcinoma 2 trials
-
New drug targets Hard-to-Treat tumors in early trial
Disease control Stopped earlyThis study tested a drug called bemarituzumab in 260 adults with solid tumors that have high levels of a protein called FGFR2b. The main goals were to see if the drug is safe and if it can shrink tumors. Participants had already tried other treatments without success.
Phase 1/2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Diet and drug combo aim to tame tumor side effects
Disease control Stopped earlyThis study tested a new drug called serabelisib combined with a diet that lowers insulin levels, with or without another chemotherapy drug, in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The goal was to see if the diet could reduce sid…
Phase 1 • Sponsor: Faeth Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Newer radiation technique may spare bladder and bowel in endometrial cancer patients
Symptom relief Stopped earlyThis trial compared two ways of giving pelvic radiotherapy after surgery for endometrial cancer: standard 3D planning versus a newer technique called IMRT. The goal was to see if IMRT could reduce side effects like bladder and bowel problems. The study enrolled 92 participants bu…
Phase 2 • Sponsor: Cancer Trials Ireland • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC